Metformin vs GLP-1 for PMOS and PCOS weight care

Choose the main goal with the clinician: cycle or androgen-related symptoms, metabolic health, weight, contraception or pregnancy. The same treatment will not necessarily address them all. Agree on a measurable outcome, monitoring and who provides any gynecology or fertility care; metabolic improvement does not guarantee pregnancy.

Review previous nutrition changes, metformin, hormone or cycle treatment, weight medicines and fertility care, including dose, duration, benefit and adverse effects. This helps the clinician avoid repeating an unsuitable plan and identify what remains unresolved. Bring prior records and clarify the main goal now; different goals may need different treatments or specialists.

Glucose, lipid and other selected results can identify metabolic risks or guide treatment, but their meaning depends on the history and the actual values. Bring dated reports rather than a summary that results were normal. The clinician decides which findings affect the plan; one insulin-resistance result does not automatically qualify a person for an obesity medicine.

Weight-loss medicines are not appropriate for weight treatment during pregnancy. Tell the prescriber promptly if pregnancy occurs or is planned. Semaglutide for weight treatment should be stopped at least two months before a planned pregnancy. Tirzepatide and Foundayo need product-specific planning and contraception review. Pregnancy and breastfeeding advice must use the exact label.

Give the clinician the full list of prescriptions, over-the-counter products and supplements, including contraception and fertility treatment. Medicines can interact or change monitoring, glucose risk and pregnancy planning. Include doses and recent changes. Do not stop another prescribed medicine yourself while arranging a PCOS or weight-management evaluation.

Review metabolic outcomes, cycle changes, tolerability, contraception, and pregnancy plans. Discuss interruptions and restarting after pregnancy or breastfeeding with the prescriber. Continue fertility or gynecology care when needed.

Metformin is a diabetes medicine and may be used for selected PCOS-related metabolic goals after assessment. It is not a dedicated approved obesity drug or an interchangeable substitute for a GLP-1 medicine. Any weight change varies; review the actual treatment goal, suitability and pregnancy plans rather than assume it is prescribed solely for weight loss.

Metformin and GLP-1 medicines act differently and serve different goals. Metformin is not interchangeable with an approved obesity medicine or a fertility treatment. Review whether the priority is glucose, weight, cycles, or pregnancy before choosing treatment.

They may be used together for an appropriate clinical reason, but the prescriber must review the goal, diabetes risk, pregnancy plans, and tolerability. Metformin does not establish automatic eligibility or coverage for a GLP-1 medicine.

Metformin can be used for selected PCOS-related needs, but it does not replace a fertility evaluation or guarantee pregnancy. Ovulation treatment and other infertility care should be directed by the gynecology or fertility team.

Ozempic and Mounjaro have diabetes indications; using a diabetes brand does not automatically make PCOS-related weight treatment covered. The plan considers the exact diagnosis, product and its rules. Compare appropriate approved options with the prescriber, and ask the plan which records and authorization are needed rather than choose a brand only on an assumed easier approval.

Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. For weight treatment, semaglutide should be stopped at least two months before planned pregnancy. Tirzepatide requires additional or non-oral contraception for four weeks after starting or increasing. Foundayo uses a 30-day precaution. Contact the prescriber promptly after a positive pregnancy test.

Discuss pregnancy plans before starting or continuing a GLP-1 weight medicine. Weight treatment is unsuitable during pregnancy, and the product may need to stop well beforehand; semaglutide requires at least two months before planned pregnancy. Agree on the exact stopping date, contraception and alternative metabolic or fertility care with the prescriber rather than continue while actively trying without a plan.